| Name | Title | Contact Details |
|---|---|---|
Dru Homer |
Vice President of Quality and Operational Excellence | Profile |
Marietta Toal |
Director, Data Management | Profile |
Kevin Brumbaugh |
Director Information Security | Profile |
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
Second Wind Lung Transplant Association Inc is a Largo, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Practice Velocity is a Belvidere, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MusclePharm is an award winning and worldwide leading sports nutrition brand. Our expansive line of clinically proven safe and effective supplements reaches all elements of the active, push-the-edge lifestyle—from muscle building, athletic performance, weight loss and general fitness.
MC-21 is a Caguas, PR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.